FDA conditionally recommends approval for amyloid imaging technology

A U.S. Food and Drug Administration (FDA) advisory panel last week said that florbetapir (Amyvid), a radioactive dye proposed for use in Positron Emission Tomography (PET) to detect amyloid buildup in the brain, could be useful pending additional data analysis and training for physicians. The Alzheimer’s Association believes that further research is needed to understand the appropriate use of florbetapir-PET imaging — or any other imaging technology — in diagnosing Alzheimer’s. Read more here: http://bit.ly/huzUgV